Abbott Laboratories
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B | $6.84B | $3.86B | $3.84B |
| Accounts Receivable | $7.93B | $6.93B | $6.57B | $6.22B | $6.49B | $6.41B | $5.43B | $5.18B |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | $5.16B | $5.01B | $4.32B | $3.80B |
| Total Current Assets | $26.00B | $23.66B | $22.67B | $25.22B | $24.24B | $20.44B | $15.67B | $14.63B |
| Property, Plant & Equipment | $11.82B | $10.66B | $10.15B | $9.16B | $8.96B | $9.03B | $8.04B | $7.56B |
| Goodwill | $24.04B | $23.11B | $23.68B | $22.80B | $23.23B | $23.74B | $23.20B | $23.25B |
| Intangible Assets (Excl. Goodwill) | $5.53B | $6.65B | $8.82B | $10.45B | $12.74B | $14.78B | $17.03B | $18.94B |
| Total Assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B | $67.89B | $67.17B |
| Liabilities | ||||||||
| Accounts Payable | $4.24B | $4.20B | $4.30B | $4.61B | $4.41B | $3.95B | $3.25B | $2.98B |
| Total Current Liabilities | $16.50B | $14.16B | $13.84B | $15.49B | $13.11B | $11.91B | $10.86B | $9.01B |
| Long-Term Debt | $9.90B | $12.63B | $13.60B | $14.52B | $17.30B | $18.53B | $16.66B | $19.36B |
| Total Liabilities | $34.58B | $33.75B | $34.61B | $37.75B | $39.39B | $39.76B | $36.80B | $36.65B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $49.78B | $47.26B | $37.55B | $35.26B | $31.53B | $27.63B | $25.85B | $24.56B |
| Total Stockholders' Equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B | $32.78B | $31.09B | $30.52B |